文献速递生殖医学

促卵泡素α生物类似药与原研药用于辅助生殖卵巢刺激的比较:系统综述与Meta分析

Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod · 2025-01-01

该系统综述与Meta分析纳入8项随机对照试验(n=2987),比较促卵泡素α生物类似药与原研药在辅助生殖卵巢刺激中的妊娠结局。结果显示,生物类似药组的活产率(RR 0.83,95%CI 0.72-0.96)、临床妊娠率(RR 0.82,95%CI 0.73-0.92)和持续妊娠率(RR 0.81,95%CI 0.70-0.94)均显著低于原研药组,而获卵数和卵巢过度刺激综合征发生率无显著差异。

要点

  • 促卵泡素α生物类似药组的活产率显著低于原研药组(RR 0.83,95%CI 0.72-0.96)。
  • 临床妊娠率(RR 0.82)和持续妊娠率(RR 0.81)在生物类似药组也显著降低。
  • 获卵数和卵巢过度刺激综合征发生率两组间无显著差异。

核心结论

  • Meta分析提示,与原研促卵泡素α相比,生物类似药组的活产率、临床妊娠率和持续妊娠率显著降低。
  • 尽管生物类似药获卵数与原研药相似,但新鲜移植后的妊娠率可能更低。

研究设计与样本

  • 系统综述与Meta分析,纳入8项随机对照试验(n=2987),发表于2015年至2023年,评估7种促卵泡素α生物类似药。
  • 检索截至2024年1月,数据库包括MEDLINE、Embase、Cochrane CENTRAL、Scopus、Web of Science、WHO、Clinicaltrials.gov等。
  • 主要结局为活产,次要结局包括临床妊娠、持续妊娠、促性腺激素使用时长和总FSH剂量、获卵数及卵巢过度刺激综合征。
  • 采用Cochrane RoB-2工具评估质量,并进行敏感性分析排除高偏倚风险研究。
  • Meta分析根据异质性(I²>50%)选择随机或固定效应模型,结果以意向性治疗原则合并,报告为风险比(RR)或加权均数差(WMD)及95%CI。

主要发现

  • 生物类似药组的活产率显著低于原研药组(RR 0.83,95%CI 0.72-0.96;I²=0%,6项研究,n=2335;中等确定性证据)。
  • 生物类似药组的临床妊娠率显著低于原研药组(RR 0.82,95%CI 0.73-0.92;I²=0%,7项研究,n=2876;低确定性证据)。
  • 生物类似药组的持续妊娠率显著低于原研药组(RR 0.81,95%CI 0.70-0.94;I²=0%,7项研究,n=1886;低确定性证据)。
  • 生物类似药组的促性腺激素使用时长较原研药组缩短(WMD -0.19天,95%CI -0.34至-0.05;I²=0%,5项研究,n=2081)。
  • 两组间总FSH剂量(WMD -34.69 IU,95%CI -74.54至5.16;I²=15.53%,5项研究,n=2081)、获卵数(WMD 0.27,95%CI -0.43至0.96;I²=10.7%,6项研究,n=1527)和卵巢过度刺激综合征发生率(RR 1.17,95%CI 0.90-1.52;I²=0%,8项研究,n=2986)无显著差异。

临床怎么用

  • 临床医生应知晓,尽管促卵泡素α生物类似药与原研药获卵数相似,但新鲜移植后的妊娠率可能更低。
  • 未来研究应聚焦于优化促卵泡素α生物类似药的生产和使用,使其妊娠率与原研药相当。

局限性

  • 本Meta分析纳入评估7种不同促卵泡素α生物类似药的随机对照试验,但合并数据呈现同质性。
  • 缺乏促卵泡素α生物类似药与原研药在每次取卵累积活产率或冻融周期活产概率方面的比较数据。
  • 纳入的随机对照试验人群主要为正常反应者,未发现针对低反应或高反应者的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is the probability of pregnancy different between women using biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART? SUMMARY ANSWER: Meta-analysis of eight randomized clinical trials (RCTs) suggests that live birth, clinical, and ongoing pregnancy rates are significantly lower with biosimilars of follitropin alfa compared to the originator. WHAT IS KNOWN ALREADY: All biosimilars of follitropin alfa have received regulatory approval by demonstrating non-inferiority in the number of retrieved oocytes compared to the originator. Nevertheless, the most clinically relevant outcome in ART for both clinicians and patients is live birth. A meta-analysis published in 2021 suggested that biosimilars of follitropin alfa are associated with lower live birth rates compared to the originator. Since then, more relevant RCTs have been published, and thus an updated critical synthesis of the available evidence is urgently warranted. STUDY DESIGN, SIZE, DURATION: A systematic review and meta-analysis were performed to compare biosimilars versus the originator of follitropin alfa in women undergoing ovarian stimulation for ART. A literature search was conducted until January 2024 in MEDLINE, Embase, Cochrane CENTRAL, Scopus, Web of Science, WHO, Clinicaltrials.gov, and others to identify eligible RCTs. The primary outcome was live birth. Secondary outcomes included clinical and ongoing pregnancy, duration of gonadotrophin administration and total FSH dose, number of oocytes retrieved, and ovarian hyperstimulation syndrome (OHSS). PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were extracted independently by two reviewers. Quality was assessed using the RoB-2 Tool by Cochrane, and a sensitivity analysis was performed by excluding studies having high risk of bias. Meta-analysis was performed using the random or fixed effects model depending on the presence or not of significant (>50%) statistical heterogeneity (I2). Results were combined using the intention-to-treat principle and are reported as risk ratio (RR) or weighted-mean-difference (WMD) with 95% CIs. MAIN RESULTS AND THE ROLE OF CHANCE: Eight RCTs (n = 2987) (published between 2015 and 2023) were identified, assessing seven biosimilar products of follitropin alfa. The number of patients included in the eligible studies ranged from 100 to 1100. Three of the RCTs were deemed to be at high risk of bias. The duration of gonadotrophin administration was shorter in the biosimilars group (WMD: -0.19 days, 95% CI: -0.34 to -0.05; I2 = 0%, 5 studies, n = 2081), while no difference was observed in the total dose of FSH (WMD: -34.69 IUs, 95% CI: -74.54 to 5.16; I2 = 15.53%, 5 studies, n = 2081). No difference was observed in the number of oocytes retrieved (WMD: 0.27, 95% CI: -0.43 to 0.96; I2 = 10.7%, 6 studies, n = 1527) and OHSS rates (RR: 1.17, 95% CI: 0.90-1.52; I2 = 0%, 8 studies, n = 2986) between the two groups. A significantly lower live birth rate was observed using the biosimilars of follitropin alfa compared to the originator in women undergoing ovarian stimulation for ART (RR: 0.83, 95% CI: 0.72-0.96; I2 = 0%, 6 studies, n = 2335; moderate certainty of evidence). Similarly, clinical pregnancy (RR: 0.82, 95% CI: 0.73-0.92; I2 = 0%, 7 studies, n = 2876; low certainty of evidence) and ongoing pregnancy rates (RR: 0.81, 95% CI: 0.70-0.94; I2 = 0%, 7 studies, n = 1886; low certainty of evidence) were lower in the biosimilars group. These results were not materially altered in the sensitivity analyses performed where studies deemed at high risk of bias were excluded. LIMITATIONS, REASONS FOR CAUTION: This meta-analysis included RCTs evaluating seven different biosimilars of follitropin alfa; however, pooled data appeared to be homogeneous. No data were available comparing biosimilars of follitropin alfa with the originator regarding cumulative live birth rate per aspiration or the probability of live birth in frozen thawed cycles. The population examined in the eligible RCTs includes mainly normal responders and no RCTs were identified focusing on poor or high responders. WIDER IMPLICATIONS OF THE FINDINGS: Clinicians should be informed that although biosimilars of follitropin alfa produce similar number of oocytes with the originator, pregnancy rates after a fresh transfer are likely to be lower. Future research should focus on optimizing the production and use of biosimilars of follitropin alfa, so that they lead to pregnancy rates comparable to the originator. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. K.I.K. and A.S. have no competing interest to disclose. E.M.K. reports personal fees and non-financial support from Merck, Ferring, IBSA, and Vianex. B.W.M. has been supported by an investigator grant from NHMRC, has received consulting fees from Organon, Merck, and Norgine, research support and non-financial support from Merck KGaA, Darmstadt, Germany. B.W.M. also reports having stocks from OBsEva. C.A.V. reports grants, personal fees, and non-financial support from Merck KGaA, Darmstadt, Germany, personal fees, and non-financial support from Merck, Sharpe and Dohme, personal fees and non-financial support from Organon, grants and non-financial support from Ferring, personal fees from IBSA, and personal fees and non-financial support from Gedeon Richter and Vianex. REGISTRATION NUMBER: Protocol for the systematic review registered in The International Prospective Register of Systematic Reviews (PROSPERO; CRD42024498237).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kiose KI, Storr A, Kolibianakis EM, et al. Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis. Hum Reprod. 2025. PMID: 39719046. doi:10.1093/humrep/deae274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。